VIVA
维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
股票代號:1873

Issue 15
NEWSLETTER
May – September 2023

VIVA Company News

Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million

On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light. Furthermore, the listed entity of Viva Biotech secured a proceed of approximately US$ 60 million through such financing. The transaction also unveiled the Company's future plan to spin off its CRO business for separate listing in the A-shares market.

Based on its SBDD strategy, Viva Biotech has achieved remarkable growth in its CRO drug discovery and development business through its continuous effort throughout the years. In particular, Viva Biotech has established its global leading position in the biopharmaceutical industry with its development in the field of protein structural analysis. Since its listing, Viva Biotech has successfully completed the mergers and acquisitions of SYNthesis and Langhua Pharmaceutical, and achieved synergy effects in the construction of an integrated platform for the research, development and manufacturing of CRO and CDMO products. Through the concerted effort of internal expansion and external partnerships, Viva Biotech's revenue hit a record-high, from approximately RMB 323 million in 2019 to approximately RMB 2.38 billion in 2022, representing a compound annual growth rate of approximately 94.57% during this period. And its gross profit increased from approximately RMB 156 million to approximately RMB 816 million in 2022, representing a compound annual growth rate of approximately 73.61%. This financing will contribute to Viva Biotech in its introduction of strategic investors, as well as in its future A-shares listing plan. This proved Viva Biotech’s effective integration of its intrinsic advantages and capital empowerment, demonstrating its forward-thinking approach and ambitious goals.

Viva Biotech (1873.HK) Announces 2023 Interim Results： Solid Growth in Main Business, Significant Rebound in Profitability

On August 29, 2023, Viva Biotech Holdings Group announced that during the period ended June 30, 2023 (the “Reporting Period”), the revenue of the Group during the Reporting Period increased by approximately 3.0% from RMB1,108.7 million for the corresponding period of last year to RMB1,142.2 million; and the gross profit increased by approximately 17.7% from RMB345.0 million for the corresponding period of last year to RMB406.0 million. The Company’s adjusted non-IFRS net profit increased by approximately 64.2% from RMB89.0 million for the corresponding period of last year to RMB146.1 million. This was mainly attributable to the investment income from successful exit of portfolio companies as well as the positive contribution from the changes in CDMO product structures.

Issue 15
NEWSLETTER
May – September 2023

VIVA Company News

Viva Biotech Awarded Successively "Top 20 Chinese R&D Enterprises in 2023" and Langhua Awarded "Top 20 Chinese CDMO Enterprises in 2023"

During the recent "2023 High-Quality Development Conference of the Great Health Industry and the 8th China Pharmaceutical R&D and Innovation Summit(PDI)", the highly anticipated "2023 China Pharmaceutical Industry R&D Strength Ranking Series List" was announced. Viva Biotech has once again demonstrated its exceptional capabilities and secured its position among the " Top 20 Chinese R&D Enterprises in 2023". Furthermore, our subsidiary, Langhua Pharmaceutical, was recognized as one of the "Top 20 Chinese CDMO Enterprises in 2023".

Viva Biotech and its subsidiary Langhua Pharmaceutical have been recognized for their comprehensive strength in the pharmaceutical industry, winning two awards in a row at the "2023 High-Quality Development Conference of the Great Health Industry and the 8th China Pharmaceutical R&D and Innovation Summit". Viva has consistently been driven by innovation, deep resource integration, and a continuous commitment to enhancing CRO/CDMO service capabilities. For our CRO business, we have built several core technology platforms, including: the PROTAC technology platform, protein production, preparation and structure biology platform, Cryo-EM technology platform, membrane protein research technology, hit discovery platform, bioassay platform, computer-aided drug design (CADD) and artificial intelligence in drug discovery (AIDD), medicinal chemistry, etc. By fostering synergistic development between biology and chemistry, Viva is dedicated to delivering complete value to customers worldwide.

Viva Biotech and DP Technology Join Forces to Advance RNA-targeted Small Molecule Drug Discovery Based on AI4S

On May 23rd, 2023, Viva Biotech (Shanghai) Ltd. ("Viva Biotech") and DP Technology Co., Ltd. ("DP Technology") announced that they have entered into a strategic partnership to fully integrate advantageous resources and work closely together to advance RNA-targeted small molecule drug discovery based on AI4S, given the synergies and complementarities of their respective businesses and technologies.

Under the terms of the strategic collaboration agreement, DP Technology will provide its existing Hermite® Drug Computing Design Platform in the AI4S field to strengthen structure-based drug design, particularly in RNA-targeted small molecule drug discovery, and jointly build a brand-new targeted compound library with Viva Biotech. Meanwhile, based on Viva's technological advantages in structural biology, affinity-based drug screening, lead compound validation, and other early-stage drug discovery fields, and combined with DP Technology's algorithms of Uni-EM, Uni-FEP, Uni-Mol, the two parties will jointly build an integrated platform for RNA-targeted small molecule drug discovery based on AI4S, which achieved both dry and wet approaches to drug discovery, as well as the evaluation of compound drug-likeness, aims to further enhance the efficiency of RNA-targeted small molecule drug screening and discovery.

VIVA Linkedin

Research & Development Progress

ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors

ABM Therapeutics, invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company. Recently they announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignant brain tumors in China. This is the second clinical study of ABM-1310 in China.

The newly opened study (NCT05892653) is a phase I, open-label, multicenter clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer efficacy of ABM-1310 in patients with BRAF V600X mutant relapsed and drug resistant primary malignant brain tumors, with the goal to determine the optimal/recommended dose for phase 2 studies.

ABM Therapeutics receives IND approval in China for MEK inhibitor ABM-168

ABM Therapeutics, invested and incubated by Viva BioInnovator (VBI), announced today that its IND application for ABM-168, a self-developed MEK1/2 inhibitor has been approved by the National Medical Products Administration (NMPA) to conduct Phase 1 clinical trials in patients with advanced solid tumors, especially patients with brain metastases or primary brain tumors, aiming to explore the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-168.

ABM-168 is a highly potent allosteric MEK1/2 inhibitor. It has shown strong anti-tumor activity when used alone, or in combination with other drugs in pre-clinical animal models. Pre-clinical research has also shown that ABM-168 had an excellent ability to penetrate the blood-brain barrier and could effectively kill brain metastatic cancer cells or malignant brain tumor cells. ABM-168 has been granted its IND by the U.S. FDA in October 2022. A first in human Phase 1 clinical trial (NCT05831995) has been opened in several cancer centers in the United States.

Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study

Arthrosi Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biotechnology company. Recently they have announced they have received written response from the U.S. Food and Drug Administration (FDA) related to their End-of-Phase 2 briefing package for AR882, its lead drug candidate for gout treatment. AR882 is a highly potent, selective, and once daily dosing next-gen URAT1 inhibitor. The feedback from the FDA supports Arthrosi progressing with its planned Phase 3 clinical program.

Research & Development Progress

U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation

ABM Therapeutics (ABM), invested and incubated by Viva BioInnovator (VBI), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with glioblastoma (GBM) bearing BRAF V600 mutation.

DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)

DTx Pharma, invested and incubated by Viva BioInnovator (VBI), is a biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotides (FALCON) platform. Recently they announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx-1252, an investigational FALCON small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). CMT1A is a progressive, neuromuscular, autosomal-dominant disease that leads to life-long loss of muscle function and disability.

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage biopharmaceutical company developing innovative drug candidates in immune oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the nomination of a drug candidate, a Negative Allosteric Modulator (NAM) of protease-activated receptor 2 (PAR2), DT-9045, with first-in-class potential for immuno-oncology, particularly for fibrotic tumors.

VVN539, a dual-target innovative drug for glaucoma independently developed by VivaVision, reached the primary research endpoint in the Phase II clinical trial in the United States

Recently, VivaVision Biotech-an innovative ophthalmic drug company, which is invested and incubated by Viva Biotech announced that its dual-target drug VVN539 has reached the primary study endpoint in the US phase II clinical trial for patients with open-angle glaucoma or ocular hypertension.

ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor

ABM Therapeutics, invested and incubated by Viva BioInnovator (VBI), is an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases. Recently they announced that the first patient was successfully dosed with ABM-168 in the United States.

Business Progress

AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease

AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical stage biopharmaceutical company. Recently on August 10, 2023 at 08:00 AM (ETD) they announced the opening of the first clinical trial site in China for its Phase 2, open-label study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies. AceLink is developing the next generation oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders of glycosphingolipid metabolism.

The phase 2 study is now actively screening and enrolling patients across multiple sites in China. Dr. Nan Chen at Shanghai's Ruijin Hospital is the Principal Investigator (PI) leading the efforts. In addition to Ruijin Hospital, five other sites are expected to open in Q3 of 2023. AceLink expects top line results in 2H 2024.

Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs

Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics. As part of the research agreement, Pfizer will support Riparian's efforts to discover further drug targets leading to vasoprotection and will have an option on such targets.

Investment Progress

DTx Pharma Reached the Acquisition Agreement with Novartis

DTx Pharma, invested and incubated by Viva BioInnovator (VBI), is a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON™) platform. Recently they announced that it has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma's lead program is currently in preclinical development, with FDA Orphan Drug Designation, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).

Investment Progress

Arthrosi Secures $75M in Series D Financing

Arthrosi Therapeutics, invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biotechnology company. Recently they announced the successful securing of $75 million in Series D financing. This round is led by Guangrun Health Industry (Hong Kong) Co. Limited and backed by a consortium of investors, including Reichstein Biotech (HK) Co. Limited, a subsidiary of ApicHope Pharmaceuticals. The participation of these notable investors underscores their continued confidence and commitment to the development of AR882. This financing represents another milestone in the development of AR882, a highly potent and selective next-gen URAT1 inhibitor delivered in a once-daily immediate-release oral capsule. AR882 has the potential to change the treatment paradigm for gout, addressing critical aspects such as serum uric acid (sUA) levels, flares, and tophi reduction.

VivaVision Announced the Completion of Over 100 million RMB in Series D2 Financing

VivaVision, a company incubated and invested by Viva Biotech, recently announced the completion of Series D2 financing round over 100 million RMB. This financing round was jointly completed by V Capital, Shengze Investment, Sunbow Capital, VVB Fund and other institutions. The completion of the new financing round not only represents a significant affirmation of VivaVision's innovative achievements but also indicates positive expectations for its long-term development.

The proceedings from this round will be used for the advancement of clinical trials of multiple ophthalmic innovative drugs, preclinical pipeline research and development, and the expansion of technology innovation platforms. The company is actively accelerating commercial cooperation on the mid-to-late-stage pipeline and pursuing forward-looking industrialization strategies.

About Viva Biotech

Listing Date
2019.05.09
Price (2023.10.5)
HKD 1.30
52 WK Range
HKD 1.16-2.26
Market Cap (2023.10.5)
HKD 2.554B

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage structure-based drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of December 31, 2022, Viva Biotech has provided drug R&D and production services to 2,076 biotech and pharmaceutical clients around the world. We have invested and incubated 91 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva's platform.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com